Stocktoria
Caribou Biosciences, Inc. CRBU
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-23
Caribou Biosciences, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M | $12.4M |
| R&D expense | $109.4M | $130.2M | $112.1M | $82.2M | $52.3M | $34.4M |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M | -$67.0M | -$36.1M |
| Interest expense | — | — | — | — | $8,000 | $20,000 |
| Income tax | -$550,000 | -$9,000 | $193,000 | $70,000 | $321,000 | -$1.8M |
| Net income | -$148.1M | -$149.1M | -$102.1M | -$99.4M | -$66.9M | -$34.3M |
| EPS (diluted) | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 | — |
| Operating cash flow | -$111.0M | -$138.2M | -$93.3M | -$91.0M | -$32.5M | -$33.2M |
| Free cash flow | -$112.4M | -$143.1M | -$104.9M | -$97.4M | -$34.6M | -$33.5M |
| Cash & equivalents | $12.4M | $16.3M | $51.2M | $58.3M | $240.4M | $16.0M |
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M | $36.0M |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | $54.5M | $18.2M |
| Shareholders' equity | $122.2M | $253.0M | $368.4M | $300.9M | $387.8M | -$23.4M |
Growth · year-over-year · Revenue CAGR -2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +11.7% | -71.0% | +148.9% | +44.3% | -22.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.